PharmaTelevision - Stemgent: Supplying Advanced Technologies and Research Tools to the Stem Cell Research Industry

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Stemgent: Supplying Advanced Technologies and Research Tools to the Stem Cell Research Industry

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this interview, Fintan Walton talks to Ian Ratcliffe, CEO of Stemgent - an early stage company based in Cambridge, Massachusetts. This programme explores the genesis of the idea for the company as well as the origins of funding through venture capital backing. Ian Ratcliffe explains his vision for the company’s future and discusses the need for small companies to set achievable scientific standards. He also touches on the benefits of working within a new and fast-paced scientific discipline.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

The genesis of the idea for the company and involvement in stem cell research.

Fintan Walton:

Hello and welcome to PharmaVentures business review here live in San Diego, California. On this show I have Ian Ratcliffe, who is CEO of Stemgent based in Cambridge, Massachusetts. Welcome to the show.

Ian Ratcliffe:

Thank you.

Fintan Walton:

Ian Ratcliffe, Stemgent as I said is an early stage company. It was founded in January of this year 2008. What is Stemgent all about?

Ian Ratcliffe:

So that's correct. We started January 2008 a new research products company focused on servicing the needs of the stem cell research industry. Company, the genesis of the company was some ideas that I had coming out of my background from Upstate Biotechnology which was a success with stem cell, cell signaling research company.

Fintan Walton:

Sure.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Ian Ratcliffe

Chief Executive Officer

Mr. Ian Ratcliffe, President and CEO of Stemgent Inc., was recently made a Non-Executive Director of Asterand, supplier of human tissue and human tissue-based research services. Since August 2006 he has held the position of Chairman/Owner of Enzymatics, a large scale enzyme production company. Prior to this he held various executive roles in UpstateBiologicals, including Chief Financial Officer (1997-2001) and Executive Vice President of Sales and Innovation, responsible for US and Asian sales. He was made President and Chief Operations Officer in 2004. During his time as President, Mr. Ian Ratcliffe was instrumental in the acquisition of Upstate by Serologicals, Corp. in September 2004 and was retained as President of the Upstate Division until May 2005. Ian Ratcliffe gained his first degree in Chemical Engineering from the University of Surrey, and received an MBA from Darden Graduate School of Business Administration, University of Virginia in 1994.

Stemgent

Stemgent, a life science consumable products company, was founded in January 2008 to service the needs of the stem cell research industry and to help in the advancement of stem cell science and regenerative medicine. Located in Cambridge, Massachusetts, Stemgent benefits from its proximity to leading US research centres. Prominent researchers on the company's scientific advisory board help ensure that new discoveries and research results in this complex, cutting edge discipline are quickly available to the industry. Since the recent discovery of cell reprogramming the stem cell science industry has been expanding rapidly and although Stemgent currently supplies only US businesses, its intention is to expand into the world market in the next few years.